Lorecivivint
AssetAlso SM04690, LOR
Inhibits CLK2 and DYRK1A, modulating alternative splicing and downstream Wnt signaling to reduce inflammation and protect cartilage.
- Stage
- Approved
- Modality
- Small molecule
- Target
- DYRK1A
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Knee osteoarthritis
Approved, globenewswire.com, 2 Oct 2026
Meniscal injuries
Phase 3, biosplice.com, 10 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets2
- Competitors6
Every asset’s record: target, stage, trials and the evidence behind it.